Received Mar 10, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMRV | MEASLES + MUMPS + RUBELLA + VARICELLA (PROQUAD) | MERCK & CO. INC. | UNK | Z014409 | — |
Confirmed no symptomatic AE. Permission to contact HCP granted. No additional AE.; Inbound call from nurse calling to report TE for PROQUAD that had an excursion on 20-JAN-2026. The caller reports that a dose was administered to patient on 22-JAN-2026.; This spontaneous report was received from a nurse and refers to a specific patient of unknown age and gender. The patient's medical history, concurrent conditions and concomitant therapies were not reported. On 20-Jan-2026, a temperature excursion (TE) for Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (PROQUAD) occurred. On 22-Jan-2026, the patient was vaccinated with a dose of the Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (PROQUAD) (lot #Z014409 with valid expiration date reported as 10-Mar-2027) (dose, route of administration and vaccination site were not reported) administered for prophylaxis (product storage error). The vaccine was reconstituted with sterile diluent, solution for injection (lot # and expiration date were not reported). No symptomatic adverse event (AE) was confirmed. No additional adverse event (AE) was reported (no adverse event). No product quality complaint (PQC) was noted.
DILUENT MRK INJ